Nuvectis Pharma Inc Net Assets
Nuvectis Pharma Inc net assets. Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has net assets worth $9.08 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.38 Million) and total liabilities ($13.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Nuvectis Pharma Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.08 Million |
| % of Total Assets | 40.59% |
| Annual Growth Rate | 22.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 130.48 |
Net Assets of Nuvectis Pharma Inc (2020–2025)
Net assets of Nuvectis Pharma Inc from 2020 to 2025. This chart illustrates how Nuvectis Pharma Inc's net assets have evolved over time, based on quarterly financial data. See NVCT net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Nuvectis Pharma Inc (2020–2025)
The table below shows the annual net assets of Nuvectis Pharma Inc from 2020 to 2025. For live market cap and overall valuation, see Nuvectis Pharma Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.41 Million | +89.57% |
| 2024-12-31 | $9.71 Million | -20.39% |
| 2023-12-31 | $12.20 Million | -14.19% |
| 2022-12-31 | $14.22 Million | +229.17% |
| 2021-12-31 | $-11.01 Million | -265.61% |
| 2020-12-31 | $6.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nuvectis Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9967700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Nuvectis Pharma Inc Net Assets Breakdown (December 2025)
Nuvectis Pharma Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $118.10 Million | 641.39% |
| Total Equity | $18.41 Million | 100.00% |
Nuvectis Pharma Inc Competitors by Market Cap
The table below lists competitors of Nuvectis Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Siantar Top Tbk
JK:STTP
|
$631.36 Million |
|
Stingray Group Inc
TO:RAY-A
|
$631.50 Million |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
$631.61 Million |
|
Carasso
TA:CRSO
|
$631.75 Million |
|
Science Environmental Protection Co. Ltd. A
SHG:688480
|
$631.20 Million |
|
Prashkovsky
TA:PRSK
|
$631.18 Million |
|
Wereldhav B-Sicafi
BR:WEHB
|
$631.16 Million |
|
Walton Advanced Engineering Inc
TW:8110
|
$630.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuvectis Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,713,000 to 18,413,000, a change of 8,700,000 (89.6%).
- Net loss of 26,442,000 reduced equity.
- New share issuances of 31,210,000 increased equity.
- Other factors increased equity by 3,932,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.44 Million | -143.61% |
| Share Issuances | $31.21 Million | +169.5% |
| Other Changes | $3.93 Million | +21.35% |
| Total Change | $- | 89.57% |
Book Value vs Market Value Analysis
This analysis compares Nuvectis Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 22.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $19.34 | x |
| 2021-12-31 | $-0.87 | $19.34 | x |
| 2022-12-31 | $1.12 | $19.34 | x |
| 2023-12-31 | $0.78 | $19.34 | x |
| 2024-12-31 | $0.57 | $19.34 | x |
| 2025-12-31 | $0.84 | $19.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuvectis Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -143.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.72x
- Recent ROE (-143.61%) is below the historical average (-108.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.00K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.79 Million |
| 2022 | -132.13% | -12608.72% | 0.01x | 1.44x | $-20.21 Million |
| 2023 | -182.44% | 0.00% | 0.00x | 1.57x | $-23.48 Million |
| 2024 | -195.61% | 0.00% | 0.00x | 1.92x | $-19.97 Million |
| 2025 | -143.61% | 0.00% | 0.00x | 1.72x | $-28.28 Million |
Industry Comparison
This section compares Nuvectis Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuvectis Pharma Inc (NVCT) | $9.08 Million | 0.00% | 1.46x | $631.34 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more